Snapshot from Jul 19, 2026 at 14:14 UTC. For live data and tracking: View Live
Events / Business / Merck Group acquires Bio-Techne
Business acquisition

Merck Group acquires Bio-Techne

Analysis based on 22 articles · First reported Jun 25, 2026 · Last updated Jun 28, 2026

Sentiment
60
Attention
8
Articles
22
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The acquisition of Bio-Techne — Bio-Techne Diagnostics by Merck Group is expected to significantly boost Merck Group's life sciences division, leading to increased sales growth and EBITDA pre margin. Bio-Techne — Bio-Techne Diagnostics shareholders will benefit from a substantial premium, while the broader life sciences market may see increased M&A activity as companies position themselves for growth in research and development.

biotechnology pharmaceuticals life sciences
Event Summary

Merck Group has agreed to acquire Bio-Techne — Bio-Techne Diagnostics Corporation for $11.3 billion in cash, marking its largest acquisition in over a decade. The deal, which represents a 36% premium to Bio-Techne — Bio-Techne Diagnostics's one-month volume-weighted average trading price, aims to expand Merck Group's life sciences business and reduce its reliance on marketed drugs. Bio-Techne — Bio-Techne Diagnostics, a global provider of life science tools, analytical technologies, and consumables, will strengthen Merck Group's presence in high-growth areas such as multi-omics, spatial biology, precision diagnostics, and cell and gene therapy. The acquisition is the first major move under new CEO Kai Beckmann, who has pledged a focus on M&A to bolster product offerings. The transaction is expected to close by late 2026 or early 2027, subject to regulatory and shareholder approvals, and is anticipated to be immediately accretive to sales growth and EBITDA pre margin for Merck Group.

Entities Involved
stock
Merck Group
Merck Group is acquiring Bio-Techne — Bio-Techne Diagnostics Corporation to expand its life sciences business, reduce reliance on marketed drugs, and strengthen its position in high-growth areas like multi-omics and cell and gene therapy. This acquisition is its largest in over a decade and is expected to be immediately accretive to sales growth and EBITDA pre margin.
Importance 100.0 Sentiment 65.0
subs
Bio-Techne — Bio-Techne Diagnostics
Bio-Techne — Bio-Techne Diagnostics is being acquired by Merck Group for $11.3 billion, representing a significant premium for its shareholders. The company's portfolio of life science reagents, analytical instruments, and clinical diagnostics will be integrated into Merck Group's life sciences division, expanding its global reach and innovation capabilities.
Importance 100.0 Sentiment 75.0
per
Kai Beckmann
Kai Beckmann, the new CEO of Merck Group, is overseeing his first major acquisition with Bio-Techne — Bio-Techne Diagnostics. He has pledged a focus on M&A to bolster product offerings and sees this transaction as a key milestone in the company's strategic agenda.
Importance 80.0 Sentiment 60.0
per
Robert V. Baumgartner
Robert V. Baumgartner, Chairman of Bio-Techne — Bio-Techne Diagnostics, stated that the board concluded the deal delivers substantial, near-term value to its shareholders.
Importance 30.0 Sentiment 70.0
per
Jean-Charles Taveau
Jean-Charles Taveau, CEO Life Science at Merck Group, emphasized that Bio-Techne — Bio-Techne Diagnostics will add scale through its catalog of consumables and increase Merck Group's presence in high-growth areas.
Importance 30.0 Sentiment 60.0
per
Kim Kelderman
Kim Kelderman, President and CEO of Bio-Techne — Bio-Techne Diagnostics, highlighted that the transaction is a testament to the company's achievements and will provide greater scale and expanded capabilities as part of Merck Group.
Importance 30.0 Sentiment 70.0
subs
Merck KGaA — Sigma-Aldrich
Merck KGaA — Sigma-Aldrich was a life sciences tool manufacturer acquired by Merck Group in 2015 for $17 billion, serving as a precedent for the current Bio-Techne — Bio-Techne Diagnostics acquisition and highlighting Merck Group's long-term strategy in the life sciences sector.
Importance 20.0 Sentiment 0.0
stock
SpringWorks Therapeutics
SpringWorks Therapeutics was acquired by Merck Group in April 2025 for $3.9 billion, which was its largest acquisition in years prior to the Bio-Techne — Bio-Techne Diagnostics deal.
Importance 10.0 Sentiment 0.0
stock
Thermo Fisher Scientific
Thermo Fisher Scientific is mentioned as another big U.S. life-science company that has made multibillion-dollar acquisitions, indicating a trend in the industry that Merck Group is following.
Importance 5.0 Sentiment 0.0
stock
Danaher Corporation
Danaher Corporation is mentioned as another big U.S. life-science company that has made multibillion-dollar acquisitions, indicating a trend in the industry that Merck Group is following.
Importance 5.0 Sentiment 0.0
Relationships
Merck Group related ↔ Thermo Fisher Scientific
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.